BRPI0809656A2 - Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica - Google Patents

Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica

Info

Publication number
BRPI0809656A2
BRPI0809656A2 BRPI0809656-2A2A BRPI0809656A BRPI0809656A2 BR PI0809656 A2 BRPI0809656 A2 BR PI0809656A2 BR PI0809656 A BRPI0809656 A BR PI0809656A BR PI0809656 A2 BRPI0809656 A2 BR PI0809656A2
Authority
BR
Brazil
Prior art keywords
prophylatic
atropisomer
compound
pharmaceutical composition
therapeutic agent
Prior art date
Application number
BRPI0809656-2A2A
Other languages
English (en)
Inventor
Kazumasa Aoki
Hiroyuki Tsuruoka
Noriyuki Hayashi
Juri Yoshida
Yusuke Asoh
Original Assignee
Daiichi Sankyo Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Daiichi Sankyo Co Ltd filed Critical Daiichi Sankyo Co Ltd
Publication of BRPI0809656A2 publication Critical patent/BRPI0809656A2/pt
Publication of BRPI0809656B1 publication Critical patent/BRPI0809656B1/pt
Publication of BRPI0809656B8 publication Critical patent/BRPI0809656B8/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
BRPI0809656A 2007-04-09 2008-04-08 atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica BRPI0809656B8 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2007101938 2007-04-09
JP2007-101938 2007-04-09
PCT/JP2008/056907 WO2008126831A1 (ja) 2007-04-09 2008-04-08 ピロール誘導体のアトロプ異性体

Publications (3)

Publication Number Publication Date
BRPI0809656A2 true BRPI0809656A2 (pt) 2014-10-07
BRPI0809656B1 BRPI0809656B1 (pt) 2019-07-09
BRPI0809656B8 BRPI0809656B8 (pt) 2021-05-25

Family

ID=39863928

Family Applications (1)

Application Number Title Priority Date Filing Date
BRPI0809656A BRPI0809656B8 (pt) 2007-04-09 2008-04-08 atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica

Country Status (14)

Country Link
US (2) US8524918B2 (pt)
EP (1) EP2133330B1 (pt)
JP (1) JP5363312B2 (pt)
KR (2) KR101477579B1 (pt)
CN (1) CN101679243B (pt)
BR (1) BRPI0809656B8 (pt)
CA (1) CA2683059C (pt)
DK (1) DK2133330T3 (pt)
ES (1) ES2448498T3 (pt)
IL (1) IL201261A0 (pt)
PL (1) PL2133330T3 (pt)
PT (1) PT2133330E (pt)
TW (1) TWI444185B (pt)
WO (1) WO2008126831A1 (pt)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5767587B2 (ja) * 2008-10-08 2015-08-19 エグゼリクシス， インコーポレイテッド １−フェニルピロール化合物
JP5767586B2 (ja) * 2008-10-08 2015-08-19 エグゼリクシス， インコーポレイテッド （ヒドロキシアルキル）ピロール誘導体のアトロプ異性体
WO2010098286A1 (ja) * 2009-02-25 2010-09-02 第一三共株式会社 ミネラルコルチコイド受容体拮抗薬を含有する医薬
EP2411375B1 (en) * 2009-03-26 2013-08-28 Poxel Process for enantiomeric separation of racemic dihydro-1,3,5 triazines via preferential crystallization
HUE038950T2 (hu) * 2013-04-10 2018-12-28 Daiichi Sankyo Co Ltd Eljárás pirrol származék atropizomere elõállítására
JP6422868B2 (ja) * 2013-07-23 2018-11-14 第一三共株式会社 高血圧症の予防又は治療のための医薬
CA2922350C (en) 2013-08-27 2018-04-17 Masashi Watanabe Method for producing pyrrole derivative, and intermediate thereof
ES2707726T3 (es) 2014-06-30 2019-04-04 Astrazeneca Ab Amidas de benzoxazinona como moduladores del receptor de mineralocorticoides
KR102488167B1 (ko) * 2015-01-26 2023-01-12 다이이찌 산쿄 가부시키가이샤 피롤카르복사미드의 고형 조성물
CN109053608A (zh) * 2015-02-17 2018-12-21 华润赛科药业有限责任公司 一种旋光纯的硫代乙酸类化合物、其药物组合物和用途
CN105622531A (zh) 2015-04-03 2016-06-01 南京明德新药研发股份有限公司 轴手性异构体及其制备方法和制药用途
US20180280414A1 (en) 2015-10-13 2018-10-04 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of choroidal neovascularisation
JP6934859B2 (ja) 2016-03-24 2021-09-15 第一三共株式会社 腎疾患の治療のための医薬
ES2973248T3 (es) 2016-07-26 2024-06-19 Inst Nat Sante Rech Med Antagonista del receptor mineralocorticoide para el tratamiento de la osteoartritis
CN112707854B (zh) * 2019-10-25 2022-03-15 年衍药业(珠海)有限公司 吡咯酰胺类化合物及其用途
EP4118235A1 (en) 2020-03-11 2023-01-18 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of determining whether a subject has or is at risk of having a central serous chorioretinopathy
US20240376051A1 (en) * 2021-03-30 2024-11-14 Sunshine Lake Pharma Co., Ltd. Crystalline form of pyrrole amide compound, preparation method therefor and use thereof
AU2022264993A1 (en) * 2021-04-26 2023-11-09 Sunshine Lake Pharma Co., Ltd. Preparation method for pyrrole amide compound
US20240366632A1 (en) 2021-08-31 2024-11-07 Institut National de la Santé et de la Recherche Médicale Methods for the treatment of ocular rosacea
CN115784961A (zh) * 2021-09-10 2023-03-14 上海鼎雅药物化学科技有限公司 埃沙西林酮及其中间体的合成方法
WO2025011627A1 (zh) * 2023-07-12 2025-01-16 广东东阳光药业股份有限公司 制备吡咯甲酸化合物的方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6323208B1 (en) * 1997-09-05 2001-11-27 Pfizer Inc Atropisomers of 2,3-disubstituted-(5.6)-heteroaryl fused-pyrimidin-4-ones
WO2003027069A1 (en) * 2001-09-24 2003-04-03 Bayer Pharmaceuticals Corporation Preparation and use of pyrrole derivatives for treating obesity
US6939968B2 (en) * 2002-12-23 2005-09-06 Bristol-Myers Squibb Company Atropisomers of 3-substituted-4-arylquinolin-2-one derivatives
DE10354060A1 (de) * 2003-11-19 2005-06-02 Merck Patent Gmbh Pyrrolderivate
JP4703649B2 (ja) * 2004-07-30 2011-06-15 エグゼリクシス， インコーポレイテッド 薬学的因子としてのピロール誘導体
CA2593156C (en) * 2005-01-10 2015-05-05 Exelixis, Inc. Heterocyclic carboxamide compounds as steroid nuclear receptors ligands

Also Published As

Publication number Publication date
US8524918B2 (en) 2013-09-03
PL2133330T3 (pl) 2014-06-30
BRPI0809656B1 (pt) 2019-07-09
US20100093826A1 (en) 2010-04-15
JPWO2008126831A1 (ja) 2010-07-22
TW200901968A (en) 2009-01-16
IL201261A0 (en) 2010-05-31
HK1139942A1 (en) 2010-09-30
WO2008126831A1 (ja) 2008-10-23
KR20140048337A (ko) 2014-04-23
EP2133330A1 (en) 2009-12-16
CA2683059C (en) 2012-09-25
EP2133330B1 (en) 2014-01-01
BRPI0809656B8 (pt) 2021-05-25
PT2133330E (pt) 2014-03-31
ES2448498T3 (es) 2014-03-14
KR20090127421A (ko) 2009-12-11
US8754118B2 (en) 2014-06-17
KR101477579B1 (ko) 2014-12-30
CN101679243A (zh) 2010-03-24
US20140024696A1 (en) 2014-01-23
TWI444185B (zh) 2014-07-11
JP5363312B2 (ja) 2013-12-11
EP2133330A4 (en) 2010-08-11
CN101679243B (zh) 2012-09-26
CA2683059A1 (en) 2008-10-23
DK2133330T3 (da) 2014-03-31

Similar Documents

Publication Publication Date Title
BRPI0809656A2 (pt) Atropisômero, composto, agente profilático ou terapêutico, e, composição farmacêutica
BRPI0806531A2 (pt) Composto, composição farmacêutica, agente terapêutico, e, uso do composto.
EP1962961A4 (en) HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
BRPI0906962A2 (pt) Composto, e, composição farmacêutica
BRPI0815577A2 (pt) Peptídeo foxm1 e agente medicinal compreendendo o mesmo.
BRPI0906556A2 (pt) Composto, e, composição farmacêutica
BRPI0807078A2 (pt) Composto, e, formulação farmacêutica
BRPI0908021A2 (pt) Composto, composição farmacêutica, e, usos do composto ou da composição farmacêutica
BRPI0821115A2 (pt) Composto derivado de aminotriazol, medicamento, composição farmacêutica e uso do composto
BRPI0819218A2 (pt) Métodos, estojos e composições para administração de compostos farmacêuticos
IL199397A (en) Hetero-ring compounds, pharmaceuticals containing them, and their medicinal products
BRPI0716633A2 (pt) compostos derivados de piridin-3-ila, composiÇço farmacÊutica e uso de um composto como agente imunomodulador
BRPI0815190A2 (pt) Composto derivado de piridina, composição farmacêutica que o compreende e uso do mesmo
IL219268A (en) Anti-b79cd antibody, immunosuppressant and pharmacological agent that includes and uses it
SI2049525T1 (sl) Derivati N-(amino-heteroaril)-1H-indol-2-karboksamidov, njihova priprava in njihova terapevtska uporaba
EP2153838A4 (en) ANTI-NOROVIRUS AGENT AND COMPOSITION THEREOF
BRPI0819361A2 (pt) Composição de tratamento de cabelos e agente de tratamento
BRPI0917681A2 (pt) Composto, e, composição farmacêutica
BRPI0815578A2 (pt) Peptídeo de cdca1 e agente farmacêutico compreendendo o mesmo.
BRPI0908635A2 (pt) composto, composição farmacêutica e método de tratamento de câncer
EP2199402A4 (en) CYCLOASTRAGENOL MONOGLYCOSIDE, PREPARATION THEREOF, PHARMACEUTICAL COMPOSITION CONTAINING SAME AND USE THEREOF
BRPI0905369A2 (pt) Composição farmacêutica, composição e kit compartimentado
BRPI0816236A2 (pt) Peptídeo cdh3 e agente medicinal contendo o mesmo
EP2015740A4 (en) NEW LOW-DOSED PHARMACEUTICAL COMPOSITIONS WITH NIMESULID, PREPARATION AND USE
BRPI0807905A2 (pt) Composições medicinais aperfeiçoadas compreendendo buprenorfina e naloxona.

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B07A Application suspended after technical examination (opinion) [chapter 7.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS. (CO) 10 (DEZ) ANOS CONTADOS A PARTIR DE 09/07/2019, OBSERVADAS AS CONDICOES LEGAIS

B16C Correction of notification of the grant [chapter 16.3 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 08/04/2008 OBSERVADAS AS CONDICOES LEGAIS. PATENTE CONCEDIDA CONFORME ADI 5.529/DF